Lucia Jilaveanu, MD, PhD
Associate Professor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Appointments
Medical Oncology and Hematology
Primary
Contact Info
About
Copy Link
Titles
Associate Professor of Medicine (Medical Oncology)
Biography
Dr. Jilaveanu conducts laboratory-based clinical/translational research in melanoma focusing on predictive and prognostic biomarkers using a variety of molecular biology techniques and analytical technologies. Dr. Jilaveanu has been involved in numerous correlative studies of novel therapeutic agents for metastatic melanoma. More recently the focus of her research resides in understanding the biology and the mechanisms involved in the development of brain metastasis, uncovering novel mediators of brain metastasis and biomarker discovery for patients with melanoma that has metastasized to the brain.
Last Updated on May 05, 2025.
Appointments
Medical Oncology and Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- Genomics, Genetics, and Epigenetics
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
- Yale Medicine
Education & Training
- Associate Research Scientist
- Yale University School of Medicine (2014)
- Post-Doctoral Fellow
- Yale University, School of Medicine (2011)
- PhD
- Wesleyan University (2007)
- MD
- Carol Devila University of med. Bucharest Romania (1999)
Research
Copy Link
Overview
Medical Research Interests
Medical Oncology; Melanoma; Microarray Analysis; Neoplasm Metastasis
ORCID
0000-0001-8900-5083
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lucia Jilaveanu's published research.
Publications Timeline
A big-picture view of Lucia Jilaveanu's research output by year.
Research Interests
Research topics Lucia Jilaveanu is interested in exploring.
Harriet Kluger, MD
Veronica Chiang, MD, FAANS
Robert Camp, PhD, MD
David Rimm, MD, PhD
Mario Sznol, MD
Thuy Tran, MD, PhD
60Publications
4,441Citations
Melanoma
Neoplasm Metastasis
Publications
2025
Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1
Tran T, Sánchez-Zuno G, Osmani L, Caulfield J, Valdez C, Piecychna M, Leng L, Armstrong M, Donnelly S, Bifulco C, Clister T, Kulkarni R, Zhang L, Sznol M, Jilaveanu L, Kluger H, Kang I, Bucala R. Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1. JCI Insight 2025, 10: e191539. PMID: 41122966, PMCID: PMC12581657, DOI: 10.1172/jci.insight.191539.Peer-Reviewed Original ResearchCitationsAltmetricPhase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma
Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024, 10: e184545. PMID: 39561007, PMCID: PMC11721305, DOI: 10.1172/jci.insight.184545.Peer-Reviewed Original ResearchCitationsAltmetricMetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models
Karz A, Coudray N, Bayraktar E, Galbraith K, Jour G, Shadaloey A, Eskow N, Rubanov A, Navarro M, Moubarak R, Baptiste G, Levinson G, Mezzano V, Alu M, Loomis C, Lima D, Rubens A, Jilaveanu L, Tsirigos A, Hernando E. MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models. Pigment Cell & Melanoma Research 2024, 38: e13195-e13195. PMID: 39254030, PMCID: PMC11948878, DOI: 10.1111/pcmr.13195.Peer-Reviewed Original ResearchCitationsAltmetricTIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchCitationsAltmetricGP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchCitationsMelanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchCitationsAltmetricVascular mimicry as a facilitator of melanoma brain metastasis
Provance O, Oria V, Tran T, Caulfield J, Zito C, Aguirre-Ducler A, Schalper K, Kluger H, Jilaveanu L. Vascular mimicry as a facilitator of melanoma brain metastasis. Cellular And Molecular Life Sciences 2024, 81: 188. PMID: 38635031, PMCID: PMC11026261, DOI: 10.1007/s00018-024-05217-z.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma
Oria VO, Zhang H, Zito CR, Rane CK, Ma XY, Provance OK, Tran TT, Adeniran A, Kluger Y, Sznol M, Bosenberg MW, Kluger HM, Jilaveanu LB. Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma. Cellular And Molecular Life Sciences 2022, 79: 377. PMID: 35737114, PMCID: PMC9226089, DOI: 10.1007/s00018-022-04364-5.Peer-Reviewed Original ResearchCitationsAltmetricInhibition of renalase drives tumour rejection by promoting T cell activation
Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. European Journal Of Cancer 2022, 165: 81-96. PMID: 35219026, PMCID: PMC8940682, DOI: 10.1016/j.ejca.2022.01.002.Peer-Reviewed Original ResearchCitationsAltmetric
News
Copy Link
News
- May 14, 2026
Why Does Melanoma Spread to the Brain? A Yale Team Is Chasing the Answer.
- May 06, 2025
Department of Internal Medicine Promotions and Appointments (May 2025)
- July 01, 2024
Melanoma Brain Metastases: New Study Offers Insight for More Effective Cancer Treatment
- June 05, 2023
Discoveries & Impact (June 2023)
Get In Touch
Copy Link